Table 4.

Average fold change in transcriptional expression relative to DMSO control at 48 h following treatment with 10 μM TGFβRis

Gene	Category	Ly2109761	BMT-A	BMT-B
TGFβ1	TGFβ ligands	−3.86 ± 0.47	−1.80 ± 0.30	−1.64 ± 0.42
TGFβ2	TGFβ ligands	−2.18 ± 0.24	−1.94 ± 0.26	−1.54 ± 0.3
TGFβ3	TGFβ ligands	−5.33 ± 0.28	−9.34 ± 0.34	0.98 ± 0.13
TGFβRI	TGFβ receptors	−1.53 ± 0.14	−1.34 ± 0.22	−1.46 ± 0.22
TGFβRII	TGFβ receptors	5.16 ± 0.18	7.57 ± 0.53	2.74 ± 0.16
TGFβRIII	TGFβ receptors	18.24 ± 10.73	23.75 ± 2.39	8.93 ± 0.52
ACTA2	Myofibroblast marker	−2.75 ± 0.20	−7.85 ± 0.64	−1.85 ± 0.16
Tagln	Myofibroblast marker	−4.3 ± 0.46	−10.75 ± 1.02	−3.32 ± 0.38
Cdh1	Epithelial marker	34.29 ± 4.99	13.38 ± 2.02	18.43 ± 1.48
VIM	Mesenchymal marker	1.14 ± 0.05	2.18 ± 0.06	1.64 ± 0.11
MMP2	MMP2 EMT marker	1.98 ± 0.13	2.53 ± 0.19	2.03 ± 0.22
COL1A1	Collagens	−2.61 ± 0.11	−4.05 ± 0.42	−2.24 ± 0.17
COL11A1	Collagens	−4.88 ± 0.26	−7.99 ± 0.99	−2.94 ± 0.20
ELN	Elastin	−87.63 ± 7.50	−58.11 ± 4.51	−12.25 ± 1.73

Bold text denotes notable differences (≥1.75-fold) between BMT-B compared with BMT-A and LY2109761 responses (average from three experiments ±SEM).